Follow The Filings

TRAX First Tracks Biotherapeutics

First Tracks Biotherapeutics earnings company data as of 4:47 AM ET 10/24

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by TRAX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All TRAX insider trades
  • None no insider bought on the open market
  • $66.8M sold by 2 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. J. Anthony Ware Director
    Sale
    $1.8M 39,265 shares at $44.78 72% of stake
    Traded Sep 2 Filed Sep 4
    ↗
  2. EcoR1 Capital, LLC 10% owner
    Sale
    $65M 4,705,575 shares at $13.81 60% of stake
    Traded Apr 20 Filed Apr 22
    ↗

Also filed in the last 12 months, not counted as buying or selling: 8 option exercises and 1 other transaction.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
8-K 1.01,9.01 Filing Doc
8-K 1.01,3.02,7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
424B3 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01 Filing Doc
424B3 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B3 Filing Doc

Source: SEC EDGAR submissions, updated 4 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.